DuPont de Nemours, Inc. R&D decreased by 66.4% to $47.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.0%, from $50.00M to $47.00M.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $133.00M | $137.00M | $148.00M | $143.00M | $141.00M | $129.00M | $123.00M | $127.00M | $125.00M | $128.00M | $125.00M | $134.00M | $127.00M | $50.00M | $142.00M | $140.00M | $47.00M |
| QoQ Change | — | +3.0% | +8.0% | -3.4% | -1.4% | -8.5% | -4.7% | +3.3% | -1.6% | +2.4% | -2.3% | +7.2% | -5.2% | -60.6% | +184.0% | -1.4% | -66.4% |
| YoY Change | — | — | — | — | +6.0% | -5.8% | -16.9% | -11.2% | -11.3% | -0.8% | -1.6% | +7.2% | -0.8% | -60.0% | +6.0% | +10.2% | -6.0% |